ImpediMed Limited (ASX: IPD) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

ImpediMed Limited Chart and Price Data

Fundamentals Data provided by Morningstar.

Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • ImpediMed Limited (ASX: IPD)
    Latest News

    ⏸️ Investing

    2 growing biotech stocks for your portfolio in 2015

    Neuren Pharmaceuticals Ltd (ASX:NEU) and Impedimed Limited (ASX:IPD) could be just the ticket for improving your portfolio returns in the…

    Read more »

    ⏸️ Investing

    5 ASX stocks smashed by the market today

    ASX closes up 0.1%, but these five were smashed

    Read more »

    ⏸️ Investing

    Here's why this healthcare stock rocketed up 30% yesterday: Is there more to come?

    Impedimed Limited's (ASX:IPD) CEO Richard Carreon said: “This is a real game-changer".

    Read more »

    a woman
    ⏸️ Investing

    4 stocks soaring on the ASX today

    Want to know why some of these stocks are up more than 15%? Here's our view

    Read more »

    Frequently Asked Questions

    No, Impedimed does not pay shareholder dividends at this time.

    Impedimed Limited listed on the ASX on 24 October 2007.

    IPD ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About ImpediMed Limited

    Impedimed Ltd (ASX: IPD) is a global leader in the design and manufacture of medical devices that use bioimpedance spectroscopy (BIS) technologies in the non-invasive clinical assessment of fluid and tissue composition.

    The company's products are typically used to assess and monitor lymphedema and heart failure, as well as to measure patients' tissue composition and fluid status. They also have general health applications in weight management, nutritional issues, and assessing bone content.

    As well, Impedimed offers a cloud-based digital platform to manage patient data. The company is based in Australia and generates most of its revenue in North America. 

    Profile

    since

    Note